Cosmo is forecast to grow earnings and revenue by 42% and 26.7% per annum respectively. EPS is expected to grow by 42.1% per annum. Return on equity is forecast to be 13.5% in 3 years.
Key information
42.0%
Earnings growth rate
42.06%
EPS growth rate
Pharmaceuticals earnings growth
10.6%
Revenue growth rate
26.7%
Future return on equity
13.48%
Analyst coverage
Good
Last updated
08 Jul 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
WBAG:COPN - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
217
58
97
84
5
12/31/2027
179
50
84
70
5
12/31/2026
107
1
12
16
6
12/31/2025
104
-4
-18
-12
N/A
9/30/2025
143
28
24
31
N/A
6/30/2025
182
60
67
74
N/A
3/31/2025
225
97
112
118
N/A
12/31/2024
267
133
157
162
N/A
9/30/2024
226
96
127
130
N/A
6/30/2024
185
59
98
97
N/A
3/31/2024
139
24
58
60
N/A
12/31/2023
93
-11
18
23
N/A
9/30/2023
99
0
21
29
N/A
6/30/2023
104
11
24
36
N/A
3/31/2023
103
14
25
35
N/A
12/31/2022
102
17
26
33
N/A
9/30/2022
90
26
17
24
N/A
6/30/2022
78
35
8
16
N/A
3/31/2022
72
28
6
14
N/A
12/31/2021
65
22
4
13
N/A
9/30/2021
64
6
8
16
N/A
6/30/2021
63
-11
12
19
N/A
3/31/2021
62
-9
8
16
N/A
12/31/2020
61
-8
5
13
N/A
9/30/2020
64
-7
-1
6
N/A
6/30/2020
67
-7
-8
0
N/A
3/31/2020
65
-16
-22
-9
N/A
12/31/2019
62
-24
-36
-19
N/A
9/30/2019
56
-28
N/A
-17
N/A
6/30/2019
50
-31
N/A
-15
N/A
3/31/2019
58
-24
N/A
-12
N/A
12/31/2018
66
-18
N/A
-10
N/A
9/30/2018
69
-20
N/A
-10
N/A
6/30/2018
73
-23
N/A
-11
N/A
3/31/2018
70
-28
N/A
-10
N/A
12/31/2017
68
-32
N/A
-9
N/A
9/30/2017
68
-18
N/A
-6
N/A
6/30/2017
69
-4
N/A
-2
N/A
3/31/2017
69
8
N/A
10
N/A
12/31/2016
68
19
N/A
22
N/A
9/30/2016
70
18
N/A
18
N/A
6/30/2016
72
16
N/A
14
N/A
3/31/2016
66
132
N/A
-13
N/A
12/31/2015
61
248
N/A
-39
N/A
9/30/2015
60
241
N/A
-13
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COPN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: COPN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: COPN is expected to become profitable in the next 3 years.
Revenue vs Market: COPN's revenue (26.7% per year) is forecast to grow faster than the Austrian market (4.7% per year).
High Growth Revenue: COPN's revenue (26.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COPN's Return on Equity is forecast to be low in 3 years time (13.5%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/08 01:40
End of Day Share Price
2026/07/08 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo N.V. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.